Eleven Bio's VB4-845 shows potential anti-tumor effect in preclinical testing; shares ahead 8% premarket

|By:, SA News Editor

Eleven Biotherapeutics (NASDAQ:EBIO) perks up 8% premarket on increased volume in response to its announcement of positive preclinical data on VB4-845, the active ingredient in Vicinium and Proxinium and deBouganin, the de-immunized payload in its systemically administered drug candidates.

The company says the results show that VB4-845 induces the expression of a protein called HMGB1 in treated tumor cells which suggests that VB4-845 induces all three damage-associated molecular patterns that indicate immunogenic cell death, thus showing a capability of promoting a local anti-tumor immune response.

The data are being presented at the American Association of Cancer Research Annual Meeting in Washington, DC.